New Opioid-Like drug put to the test: will it be less addictive?
NCT ID NCT06453265
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new painkiller called cebranopadol, given as a nasal spray, to see how much recreational opioid users liked it compared to oxycodone and a placebo. 48 healthy volunteers who had used opioids for fun in the past took part. The goal was to measure the drug's abuse potential, which could help develop safer pain medications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cebranopadol
- What this could lead to
- If cebranopadol shows lower abuse potential than oxycodone, it could point toward a safer painkiller with less risk of addiction.
- What could go wrong
- This is a small, early-phase study in healthy recreational users, not patients in pain. Results may not predict real-world abuse or safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ABUSE, DRUG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ohio Clinical Trials, Inc.
Columbus, Ohio, 43212, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.